Myles Minter
Stock Analyst
(n/a)
# 4,648
Out of 4,648 analysts
17
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Myles Minter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Upgrades: Outperform | n/a | $595.58 | - | 2 | Nov 1, 2024 | |
| KRRO Korro Bio | Initiates: Outperform | n/a | $58.16 | - | 1 | Aug 14, 2024 | |
| NMRA Neumora Therapeutics | Initiates: Outperform | n/a | $11.17 | - | 1 | Oct 10, 2023 | |
| ARCT Arcturus Therapeutics Holdings | Initiates: Outperform | $71 | $18.00 | +294.44% | 1 | Jul 24, 2023 | |
| MRNA Moderna | Initiates: Market Perform | n/a | $54.63 | - | 1 | Jul 24, 2023 | |
| VRTX Vertex Pharmaceuticals | Initiates: Outperform | n/a | $471.12 | - | 1 | May 30, 2023 | |
| PRAX Praxis Precision Medicines | Downgrades: Market Perform | n/a | $68.33 | - | 2 | Mar 6, 2023 | |
| LRMR Larimar Therapeutics | Upgrades: Outperform | n/a | $7.74 | - | 3 | Sep 19, 2022 | |
| ALNY Alnylam Pharmaceuticals | Initiates: Outperform | n/a | $273.91 | - | 1 | Jun 7, 2022 | |
| IONS Ionis Pharmaceuticals | Upgrades: Outperform | n/a | $38.76 | - | 2 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.02 | - | 1 | Sep 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $116 | $122.21 | -5.08% | 1 | Feb 24, 2020 |
argenx SE
Nov 1, 2024
Upgrades: Outperform
Price Target: n/a
Current: $595.58
Upside: -
Korro Bio
Aug 14, 2024
Initiates: Outperform
Price Target: n/a
Current: $58.16
Upside: -
Neumora Therapeutics
Oct 10, 2023
Initiates: Outperform
Price Target: n/a
Current: $11.17
Upside: -
Arcturus Therapeutics Holdings
Jul 24, 2023
Initiates: Outperform
Price Target: $71
Current: $18.00
Upside: +294.44%
Moderna
Jul 24, 2023
Initiates: Market Perform
Price Target: n/a
Current: $54.63
Upside: -
Vertex Pharmaceuticals
May 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $471.12
Upside: -
Praxis Precision Medicines
Mar 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $68.33
Upside: -
Larimar Therapeutics
Sep 19, 2022
Upgrades: Outperform
Price Target: n/a
Current: $7.74
Upside: -
Alnylam Pharmaceuticals
Jun 7, 2022
Initiates: Outperform
Price Target: n/a
Current: $273.91
Upside: -
Ionis Pharmaceuticals
Dec 14, 2021
Upgrades: Outperform
Price Target: n/a
Current: $38.76
Upside: -
Sep 27, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.02
Upside: -
Feb 24, 2020
Initiates: Outperform
Price Target: $116
Current: $122.21
Upside: -5.08%